Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 06

1667P - Multiplexed spatial analysis by imaging mass cytometry to immunologically characterize checkpoint inhibitor colitis

Date

10 Sep 2022

Session

Poster session 06

Topics

Translational Research;  Immunotherapy;  Basic Science

Tumour Site

Presenters

Mick van Eijs

Citation

Annals of Oncology (2022) 33 (suppl_7): S758-S771. 10.1016/annonc/annonc1078

Authors

M. van Eijs1, J.J.M. ter Linde2, M.J.D. Baars3, M.M. Amini3, M.M. Laclé4, E.C. Brand2, B. Oldenburg5, Y. Vercoulen3, K.P.M. Suijkerbuijk6, F. van Wijk7

Author affiliations

  • 1 Medical Oncology / Center For Translational Immunology, UMC - University Medical Center Utrecht, 3508 GA - Utrecht/NL
  • 2 Gastroenterology / Center For Translational Immunology, UMC - University Medical Center Utrecht, 3508 GA - Utrecht/NL
  • 3 Center For Molecular Medicine, UMC - University Medical Center Utrecht, 3508 GA - Utrecht/NL
  • 4 Pathology, UMC - University Medical Center Utrecht, 3508 GA - Utrecht/NL
  • 5 Gastroenterology, UMC - University Medical Center Utrecht, 3508 GA - Utrecht/NL
  • 6 Medical Oncology Dept, UMC-University Medical Center Utrecht, 3584 CX - Utrecht/NL
  • 7 Center For Translational Immunology, UMC - University Medical Center Utrecht, 3508 GA - Utrecht/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1667P

Background

Immune checkpoint inhibitor (ICI) colitis is among the most prevalent immune-related adverse events (irAEs) of immune checkpoint blockade (ICB). Deeper pathophysiological understanding can contribute to evidence-based management of ICI colitis. While single-cell RNA sequencing studies lack tissue architectural insight, we used imaging mass cytometry (IMC) to study ICI colitis spatially in high immunological detail.

Methods

Formalin-fixed paraffin embedded colon biopsies of 18 patients with ICI colitis (4 αCTLA-4, 5 αPD-1, 9 combined [C]ICB) and 5 patients with ulcerative colitis were included. After DAPI imaging of nuclei, IMC was performed on ∼1 mm2 regions of stained tissue. Cells were segmented with the MATISSE pipeline combining DAPI and IMC data. We developed a data normalization, data clean-up and supervised cell lineage determination pipeline. To consolidate tissue findings, serum proteomic data (Olink® Target 96 Immuno-Oncology panel) in a partially overlapping cohort of 80 ICB-treated patients, of whom 14 with ICI colitis, were included. All P values are corrected for multiple testing.

Results

CD8+ T cells (CD8s) dominated the infiltrate of both αPD-1 and CICB colitis. CICB colitis showed the highest CD8 granzyme B (GzmB) production across groups (P < .01). Considering only the 14 patients with ICI colitis in the proteomics cohort, serum GzmB was also higher in CICB than αPD-1 colitis. A mixed-effects model showed that activated CD8s with CD69hiCD103hi tissue resident (TRM) like phenotype, more abundant in epithelium than lamina propria, mainly explained high GzmB levels in CICB colitis. CTCAE grade colitis had no effect. Within the CD4+ pool, we found elevated TH1/TH17 balance in CICB vs αCTLA-4 (P = .04), with αPD-1 TH1/TH17 balance in between αCTLA-4 and CICB. Consistently, TH1-associated serum protein levels of IFN-γ, TNF-α, GzmB/H/A and IL12Rβ1 were increased in CICB vs αPD-1 patients with any high-grade irAE (all P < .05).

Conclusions

Our data demonstrate that epithelial cytotoxic CD8+ TRM cells, as well as local TH1 skewing, are associated with the highest cytotoxicity in CICB colitis. These findings indicate that tissue TRM cells are direct targets of ICB and play an important role in colitis development.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Dutch Society of Gastroenterology (NVGE; Gastrostart grant).

Disclosure

K.P.M. Suijkerbuijk: Financial Interests, Institutional, Advisory Board: Novartis, BMS, AbbVie, Pierre Fabre, MSD; Financial Interests, Institutional, Invited Speaker: Roche; Financial Interests, Institutional, Research Grant: Novartis, TigaTx. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.